Sources checked October 18, 2026. FDA source snapshots are dated individually below. This page describes products, regulatory documents and research, not a treatment recommendation.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounding and generic approval are different regulatory categories. FDA explains that an approved generic meets the requirements of section 505(j), including therapeutic equivalence to its reference brand; a compounded drug has no FDA approval. This distinction comes from FDA's September 16, 2025 Q&A, archived October 12, 2026.[9]
The practical comparison starts with the actual preparation, rather than the word semaglutide alone. FDA's injectable-product notice describes multidose vials, prefilled syringes and differing concentrations, including more than one concentration from the same compounder. These are product-description differences, not a dose-conversion guide.[13]
What changed after the semaglutide shortage ended?
FDA announced the injection shortage resolved on February 21, 2025. Its April 28 update said the 503A shortage-related enforcement-discretion period had ended; the 503B period ran through May 22, 2025. These are historical dates, not a current general permission to compound.[10]
In its April 1, 2026 clarification, archived October 15, FDA describes 503A patient-specific prescriptions and restrictions on regularly making essentially copies. It describes a prescriber's documented significant difference for an identified patient. Adding vitamin B12 does not automatically avoid the copy analysis.[10]
For 503B outsourcing facilities using bulk substances, that clarification identifies two pathways: the 503B bulks list or shortage-list inclusion at compounding, distribution and dispensing. It states that semaglutide was on neither list.[10]
Separately, FDA's April 30, 2026 announcement proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. It set a June 29 comment deadline and said comments would precede a final determination. The version read here was archived September 24, 2026. A proposal is not itself a final determination.[11]
These documents describe distinct rules and dates. They do not determine whether an individual prescription or pharmacy complies with every applicable requirement. Ask the prescriber and dispensing pharmacy to identify the basis for the specific preparation being offered.[10]
What ingredients and label details should you ask about?
Ask for the exact active ingredient. FDA distinguishes semaglutide sodium and semaglutide acetate from the ingredient in approved drugs. In the agency's page archived October 15, 2026, FDA says it is unaware of a lawful basis for using those salts in compounding. A salt name should not be silently treated as the same ingredient.[12]
Ask for the complete ingredient list, concentration, container type and pharmacy name. FDA's July 26, 2024 notice, archived October 12, 2026, describes variable concentrations and instructions expressed in different units. Have the prescriber or pharmacist explain the instructions for the actual dispensed product; this page supplies no starting dose, titration schedule or syringe conversion.[13]
Ask which organization compounds the product, rather than recording only the telehealth brand. FDA's Q&A distinguishes state-licensed pharmacies, physicians and registered outsourcing facilities, with different oversight arrangements. Registration of a facility is separate from approval of a drug.[9]
What have studies of compounded semaglutide measured?
The reports measure different things: body composition, medical-record documentation and program-level weight changes. They are not interchangeable product comparisons.[5][6][7]
Chun and colleagues: three-month body-composition cohort
The January 7, 2025 paper reports a retrospective commercial-wellness cohort receiving compounded semaglutide with cyanocobalamin. It analyzed 94 people, including 81 women, over three months. Mean reported weight loss was 4.11 kg, or 4.57 percent of baseline weight. Mean fat mass declined 2.67 kg and lean mass declined 1.43 kg.[5]
Those are observations in that program, not a forecast for a reader or proof of equivalence to a branded drug. The original abstract was available; the publisher's full text was not recovered. The abstract does not describe a randomized comparator, and several authors list the commercial provider as an affiliation.[5]
Hendrix and colleagues: documentation, not weight-loss outcomes
The October 2025 study used US primary-care records from January 2021 through December 2024. Among 153,044 patients with documented semaglutide or tirzepatide use, the scientific abstract reports 8.2 percent with compounded formulations. Its separate plain-language summary says 8.3 percent; that discrepancy remains unresolved.[6]
This is a combined semaglutide-and-tirzepatide documentation study, not a semaglutide-only efficacy study or a count of everyone obtaining compounded drugs. We read the original abstract and plain-language summary through Europe PMC, not the publisher's full methods.[6]
Owen and colleagues: September 2026 Noom preprint
This September 10, 2026 preprint reports a retrospective analysis of 29,788 adults over 16 weeks. A matched subset included 3,657 people, with 1,219 in each program. The matched model estimated weight reductions of 2.6 percent in the behavioral-only program, 8.3 percent in its lower-dose compounded program and 9.1 percent in its other compounded program.[7]
This was not randomized and is not peer-reviewed evidence. Weight was self-reported, only 32.5 percent reported weight at week 16, and the analysis modeled missing data. The authors were employees or contractors of Noom. The preparation included glycine; it was not the cyanocobalamin formulation in the earlier cohort. The authors say generalization to other compounded products or approved medicines is unknown.[7]
How can you compare a clinic or pharmacy's paperwork?
Bring a short document checklist: the prescriber's name, dispensing pharmacy, active ingredient and other ingredients, concentration, container, and written instructions. Ask which details are confirmed on the label and which still need an answer. Keep a website's program description separate from the prescription and the product actually dispensed.[9][13]
For a quoted service, ask which charges cover consultation, medication, laboratory work and shipping. This is a comparison checklist, not a current price offer or payment commitment. Our semaglutide cost guide covers the separate pricing topic. Confirm current terms directly; no price is guaranteed here.
For reading a study, identify the exact formulation, population, follow-up and comparator before comparing percentages. A documentation rate is not a treatment result; a modeled result in a self-selected program is not a randomized product comparison.[6][7]
Where can you browse related clinic listings?
In Regenerated.com's September 2026 export of 9,042 US clinic records, 2,743 listed Peptide Therapy across 49 states plus DC. This is our directory's treatment-category coverage, not a count of compounded-semaglutide prescribers, dispensing pharmacies or approved products. Source: Regenerated.com clinic export, collected September 2026.
Browse Peptide Therapy clinics, or the Florida Peptide Therapy directory and Texas Peptide Therapy directory. Each listing is a starting point for checking recorded services, not an endorsement or confirmation that a particular preparation is offered. Ask the provider directly about the exact service and dispensing pharmacy.